Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The ‘miracle’ weight loss drug race has arrived in India with the launch of American drugmaker Eli Lilly’s Mounjaro last week. Priced at ₹17,500 monthly for a 5mg dose, the drug has an ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Eli Lily continues to dominate the weight loss ... loss drug market wave expertly after the success of its diabetes drug Mounjaro and weight loss drug Zepbound, which contains tirzepatide.

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Doctors field hundreds of calls about Mounjaro availability Patients now have alternatives to overseas, black market Entry gives Lilly edge over Novo Nordisk in huge market Sign up here.

Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight loss drug similar to Ozempic. Gastroenterologist Dr. Pal Manickam ...